(Q39795869)

14 September 2017

1 reference

title

Current trends of research on antidepressive treatment and prophylaxis (English)

1 reference

14 September 2017

H. Helmchen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A376221

11 April 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=376221

11 April 2023

publication date

1 May 1979

1 reference

full work available at URL

14 September 2017

https://api.elsevier.com/content/article/PII:0010440X79900142?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

https://api.elsevier.com/content/article/PII:0010440X79900142?httpAccept=text/plain

11 April 2023

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

11 April 2023

published in

Comprehensive Psychiatry

1 reference

14 September 2017

20

1 reference

14 September 2017

201-214

1 reference

14 September 2017

3

1 reference

THE USE OF LITHIUM SALTS IN AFFECTIVE DISORDERS

14 September 2017

1

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Prophylactic lithium: another therapeutic myth? An examination of the evidence to date

11 April 2023

9

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

NORMOTHYMOTICS, "MOOD-NORMALIZERS": ARE LITHIUM AND THE IMIPRAMINE DRUGS SPECIFIC FOR AFFECTIVE DISORDERS?

11 April 2023

12

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders.

11 April 2023

13

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

How long should prophylactics be continued in affective disorders?

11 April 2023

14

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Regulatory action of lithium in manic-depressive illness.

11 April 2023

16

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

A FIVE-YEAR SURVEY OF A PSYCHIATRIC SERVICE IN A GEOGRAPHICALLY DELIMITED RURAL POPULATION GIVEN EASY ACCESS TO THIS SERVICE.

11 April 2023

18

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Treatment setting and clinical depression

11 April 2023

20

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Depressive Illness in a General Practice. A Demographic Study and a Controlled Trial of Imipramine

11 April 2023

23

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Depressive Typologies and Response to Amitriptyline

11 April 2023

29

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

The right drug for the right patient

11 April 2023

31

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Sleep deprivation and clomipramine in endogenous depression

11 April 2023

33

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

EEG sleep changes as predictors in depression

11 April 2023

34

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Symptomatology of Therapy-Resistant Depressions

11 April 2023

39

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Dopamine-beta-hydroxylase: evidence for increased activity in sympathetic neurons during psychotic states.

11 April 2023

41

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Clinical significance of plasma levels of tricyclic antidepressant drugs in the treatment of depression

11 April 2023

43

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

11 April 2023

Treatment adherence

45

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy

11 April 2023

46

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Treatment of resistant depression. Contributions to genetic aspects.

11 April 2023

47

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

The relationship between response to phenelzine and acetylator status in depressed patients

11 April 2023

48

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Gastric Acid Production and Iron Metabolism in Depressive States

11 April 2023

53

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Indications for Long-Term Pharmacological Treatment of Schizophrenic Syndromes*

11 April 2023

54

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Treatment of Anxiety States by Antidepressant Drugs

11 April 2023

60

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Towards Rational Therapy with Monoamine Oxidase Inhibitors

11 April 2023

61

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

Studies on Thyroid Therapy and Thyroid Function in Depressive Patients

11 April 2023

64

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

On the slowness of action of tricyclic antidepressant drugs

11 April 2023

67

1 reference

https://api.crossref.org/works/10.1016/0010-440X(79)90014-2

11 April 2023

Identifiers

1 reference

release_7sgjd4h67vaezd2v57x442ezzq

14 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7sgjd4h67vaezd2v57x442ezzq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference